David Einhorn Neu Base Therapeutics, Inc. Transaction History

Greenlight Capital Inc

  • $1.97 Billion
  • Q4 2023

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 16, 2021
BUY
$4.63 - $7.34 $3.24 Million - $5.14 Million
700,000 Added 34.53%
2,727,027 $13.1 Million
Q3 2020

Nov 16, 2020
BUY
$7.25 - $9.71 $897,550 - $1.2 Million
123,800 Added 6.5%
2,027,027 $15.4 Million
Q2 2020

Aug 14, 2020
BUY
$6.69 - $11.51 $2.44 Million - $4.2 Million
364,765 Added 23.71%
1,903,227 $16.7 Million
Q3 2019

Nov 14, 2019
BUY
$3.15 - $6.59 $4.85 Million - $10.1 Million
1,538,462 New
1,538,462 $7.68 Million

About NeuBase Therapeutics, Inc.

NBSE Quotes by TradingView
  • Ticker NBSE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,258,700
  • Description
  • NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...
More about NBSE
Track David Einhorn's Portfolio

Track David Einhorn Portfolio

Follow David Einhorn (Greenlight Capital Inc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Greenlight Capital Inc, based on Form 13F filings with the SEC.

News

Stay updated on Greenlight Capital Inc and David Einhorn with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email